Review
Pharmacology & Pharmacy
Slavica Lazarevic, Maja Danic, Hani Al-Salami, Armin Mooranian, Momir Mikov
Summary: Despite the increasing number of new drugs, conventional drugs like azathioprine still play a valuable role in the treatment of inflammatory bowel disease (IBD). The gut microbiota has the ability to affect drug metabolism and alter clinical effectiveness, especially for complex drugs like azathioprine. This study explores the microbiota-mediated metabolism of azathioprine and provides insights for personalized thiopurine treatment of IBD.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Chemistry, Medicinal
Xin Liu, Gehang Ju, Wenyu Yang, Lulu Chen, Nuo Xu, Qingfeng He, Xiao Zhu, Dongsheng Ouyang
Summary: Escitalopram (SCIT) is a widely used antidepressant and antianxiety medication with significant interindividual variability in pharmacokinetics. This study aimed to establish a parametric population pharmacokinetic (PPK) model of SCIT for personalized dosing. The impact of covariates on clearance, including CYP2C19 phenotype, weight, and age, was evaluated. It was found that dosing regimens should be tailored based on these factors. Furthermore, the exposure to SCIT among Chinese psychiatric patients was significantly higher compared to other populations, indicating a need for further investigation.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Review
Health Care Sciences & Services
Maha Ali Alghamdi, Antonino N. Fallica, Nicola Virzi, Prashant Kesharwani, Valeria Pittala, Khaled Greish
Summary: Personalized medicine and nanomedicine are both new concepts in medical practice. Personalized medicine aims to customize therapeutic management based on a patient's personal attributes, while nanomedicine applies nanotechnology advances in medicine for diagnosis and treatment. The integration of these two fields can provide more effective treatment options tailored to individual patients.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Nutrition & Dietetics
Minoru Arakaki, Li Li, Toshiyuki Kaneko, Hiromi Arakaki, Hiromi Fukumura, Chihiro Osaki, Maki Yonamine, Yoshitaka Fukuzawa
Summary: This study introduces a personalized nutritional therapy based on blood data analysis, which has the potential to help patients with pre-disease conditions or undiagnosed malaise recover from their symptoms.
Article
Pharmacology & Pharmacy
Andre Luis Dias Araujo Mazzari, Mariella Guimaraes Lacerda, Flora Aparecida Milton, Joao Augusto Mulin Montechiari Machado, Simone Batista Pires Sinoti, Anne-Soulene Toullec, Patricia Marquez Rodrigues, Francisco de Assis Rocha Neves, Luiz Alberto Simeoni, Damaris Silveira, Jose Maria Prieto
Summary: Many medicinal plants have been shortlisted for future clinical use, but there is a lack of data on their action on key drug metabolism targets. This study evaluates the ability of these plants to modulate gene expression and activity of drug metabolism enzymes in vitro, and finds that some plants can significantly affect drug metabolism mechanisms.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Clinical Neurology
Cecilia Samieri, Hussein N. Yassine, Debora Melo van Lent, Sophie Lefevre-Arbogast, Ondine van de Rest, Gene L. Bowman, Nikolaos Scarmeas
Summary: Personalized nutrition may offer advantages in preventing dementia by incorporating individuals' dietary exposure history and biological characteristics to shape health more effectively. Further research from observational epidemiology to basic science is needed to achieve better prevention outcomes.
ALZHEIMERS & DEMENTIA
(2022)
Review
Biochemistry & Molecular Biology
Ethan Hau Yin Lam, Fengqing Yu, Sabrina Zhu, Zongjie Wang
Summary: In the past decade, personalized medicine has made significant progress in addressing patient-specific disease complexities and developing individualized treatment strategies. The emergence of 3D bioprinting has provided novel opportunities for personalized medicine, although current bioprinted constructs have limitations in achieving anatomically realistic organs with mature biological functions. This review discusses the principles and realizations of bioprinting, focusing on techniques such as extrusion printing and digital light processing (DLP). It also explores the applications of bioprinted constructs in regenerative medicine and drug discovery. Despite the challenges, bioprinting shows promise as an empowering technology to overcome critical obstacles in personalized medicine.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Muhammad Hassan Sarfraz, Aqsa Shahid, Samra Asghar, Bilal Aslam, Usman Ali Ashfaq, Hammad Raza, Miguel A. Prieto, Jesus Simal-Gandara, Francisco J. Barba, Muhammad Shahid Riaz Rajoka, Mohsin Khurshid, Abdulqadir J. Nashwan
Summary: In recent years, the relationship between gut microbiota, metabolic disorders, and diet has been discovered. Individuals have different responses to diet due to variations in their microbiome and host characteristics. Diet can shape the microbiome and impact human physiology. These findings are important for personalized nutrition strategies and improving human health.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Review
Food Science & Technology
Ingrid Rivera-Iniguez, Karina Gonzalez-Becerra, Omar Ramos-Lopez, Yolanda E. E. Perez-Beltran, Marian S. S. Chaguen-Hernandez, Erika Martinez-Lopez, Edgar J. J. Mendivil
Summary: This systematic review aims to identify genetic variants associated with lipid abnormalities for use in nutrigenetic interventions to prevent and treat dyslipidemia effectively.
MOLECULAR NUTRITION & FOOD RESEARCH
(2023)
Review
Chemistry, Medicinal
Jingai Jian, Donglin He, Songyan Gao, Xia Tao, Xin Dong
Summary: Indiscriminate drug administration may result in varying drug therapy outcomes for patients, while personalized medication offers the potential for effective drug therapy. Conventional approaches to personalized medication, such as pharmacogenomics and therapeutic drug monitoring (TDM), can only be implemented from a single perspective. The development of pharmacometabolomics provides a research method for precise drug administration by integrating environmental and genetic factors and utilizing metabolomics technology to predict different drug therapeutic responses based on baseline metabolic levels.
Review
Pharmacology & Pharmacy
Melisa Intan Barliana, Nadiya Nurul Afifah, Riezki Amalia, Laniyati Hamijoyo, Rizky Abdulah
Summary: SLE, a chronic autoimmune disease, is primarily influenced by genetic factors affecting treatment response. Research on gene polymorphisms impacting treatment is essential for advancing personalized medicine practices.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Zhichao Li, Haibo Xu, Lei Yu, Jia Wang, Qian Meng, Hongbing Mei, Zhiming Cai, Wei Chen, Weiren Huang
Summary: This research established an effective three-dimensional culture system for generating kidney cancer organoids and successfully generated 33 organoid lines from different subtypes of kidney cancer. These organoids preserved the histological architecture, mutational landscape, and transcriptional profile of the parental tumor tissues, and revealed inter- and intra-tumoral heterogeneity. Additionally, the organoids can be used for drug screening and evaluating the efficacy of immunotherapy.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Review
Chemistry, Analytical
Yuqiao Liu, Junmin Li, Shenghao Xiao, Yanhui Liu, Mingxia Bai, Lixiu Gong, Jiaqian Zhao, Dajing Chen
Summary: Precision medicine is essential for optimizing drug dosage and minimizing toxicity. Wearable sensors offer real-time and continuous drug monitoring, enabling personalized medicine and reducing healthcare costs.
Article
Health Care Sciences & Services
Giada Bianchetti, Alessio Abeltino, Cassandra Serantoni, Federico Ardito, Daniele Malta, Marco De Spirito, Giuseppe Maulucci
Summary: Self-monitoring of weight, diet, and physical activity is crucial for behavioral weight loss treatment. However, the current approaches for self-monitoring lack validation, user-friendliness, and standardized criteria. This study developed a web-based application that integrates various data and provides personalized energy balance estimation. It also established criteria for self-monitoring, leading to significant weight loss.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Noor A. A. Nahid, Julie A. A. Johnson
Summary: CYP2D6 pharmacogenetics and phenoconversion are crucial for ensuring drug safety and efficacy, but their implementation in clinical practice faces challenges.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2022)
Article
Pharmacology & Pharmacy
Erwin Dreesen, Sophie Berends, David Laharie, Geert D'Haens, Severine Vermeire, Ann Gils, Ron Mathot
Summary: Evidence for the benefits of pharmacokinetic (PK) and pharmacodynamic (PD) monitoring of infliximab in patients with Crohn's disease (CD) remains scarce. By developing a population (pop)PK/PD model, the study aimed to characterize the infliximab dose-exposure-biomarker-response relationship. Results showed that infliximab clearance and baseline fCal were influenced by various factors, with large interpatient PK and PD variability resulting in a flat dose-response curve. Model-informed dose optimization may improve the effectiveness of infliximab therapy.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Hematology
Robin Q. H. Kloos, Ron Mathot, Rob Pieters, Inge M. van der Sluis
Summary: Considerable variability in serum activity levels of PEGasparaginase can be explained by body surface area, treatment phase, and the occurrence of infection. A population pharmacokinetic model was developed to individualize PEGasparaginase treatment, providing dosing guidelines based on patient characteristics. This model can help optimize treatment outcomes for pediatric acute lymphoblastic leukemia patients.
Article
Pharmacology & Pharmacy
Tingjie Guo, Reinier M. van Hest, Lucas M. Fleuren, Luca F. Roggeveen, Rob J. Bosman, Peter H. J. van der Voort, Armand R. J. Girbes, Ron A. A. Mathot, Johan G. C. van Hasselt, Paul W. G. Elbers
Summary: Through simulation data, it was found that in model-based TDM of vancomycin in ICU patients, sampling more frequently than taking only trough samples adds no value, and dosing based on AUC(24)=500 mg center dot h/L leads to the best therapeutic effect.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Tim Preijers, Lisette M. Schutte, Marieke J. H. A. Kruip, Marjon H. Cnossen, Frank W. G. Leebeek, Reinier M. van Hest, Ron A. A. Mathot
Summary: Hemophilia A and B are bleeding disorders caused by deficiencies of clotting factor VIII and IX. Treatment involves prophylactic administration of clotting factor concentrates or desmopressin to prevent bleeding. Population pharmacokinetic analyses play a crucial role in identifying patient characteristics and optimizing individualized dosing strategies.
CLINICAL PHARMACOKINETICS
(2021)
Article
Surgery
Fay R. K. Sanders, Diederick Penning, Manouk Backes, Siem A. Dingemans, Susan van Dieren, Anne M. Eskes, J. Carel Goslings, Peter Kloen, Ron A. A. Mathot, Niels W. L. Schep, Ingrid J. B. Spijkerman, Tim Schepers
Summary: This study aims to investigate the effectiveness of a single intravenous dose of 2 g of cefazolin in preventing surgical site infections after elective implant removal following fixation of foot, ankle, and/or lower leg fractures. The multicenter, double-blind placebo-controlled trial will compare the proportion of patients with SSIs at 90 days post-operation. If proven effective, this could potentially impact current guidelines and suggest the use of prophylactic antibiotics in implant removal surgeries.
Article
Oncology
Charlotte Stroes, Sandor Schokker, Remco J. Molenaar, Ron A. A. Mathot, Maarten F. Bijlsma, Stephanie O. van der Woude, Joao P. Belo Pereira, Gerrit K. J. Hooijer, Rob H. A. Verhoeven, Annemieke Cats, Cecile Grootscholten, Johanna W. van Sandick, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Nadia Haj Mohammad, Jelle P. Ruurda, Sybren L. Meijer, Maarten C. C. M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W. M. van Laarhoven
Summary: The study assessed the feasibility of administering six cycles of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy and esophagectomy in esophageal adenocarcinoma. Although toxicity was a main reason for early discontinuation, efficacy results were promising, especially for patients with ERCC1 negative tumor expression. Further research is needed to determine the potential benefits of adjuvant chemotherapy for specific subgroups like ERCC1 negative patients.
Article
Hematology
Laura H. Bukkems, Jessica M. Heijdra, Nico C. B. de Jager, Hendrika C. A. M. Hazendonk, Karin Fijnvandraat, Karina Meijer, Jeroen C. J. Eikenboom, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Marjon H. Cnossen, Ron A. A. Mathot
Summary: Recent studies have shown that perioperative treatment of von Willebrand disease patients with VWF/FVIII concentrate may lead to VWF and/or FVIII levels outside of target range. Pharmacokinetic-guided dosing and integrated population PK models may improve dosing accuracy and quality of care. This study developed a population PK model describing VWF:Act and FVIII levels, showing how VWF:Act impacts FVIII clearance and half-life.
Article
Pharmacology & Pharmacy
Tim Preijers, Ri Liesner, Hendrika C. A. M. Hazendonk, Pratima Chowdary, Mariette H. E. Driessens, Dan P. Hart, Britta A. P. Laros-van Gorkom, Felix J. M. van der Meer, Karina Meijer, Karin Fijnvandraat, Frank W. G. Leebeek, Ron A. A. Mathot, Marjon H. Cnossen
Summary: This study validated a previously published population PK model for perioperative use of FVIII concentrates, showing that the model accurately described the collected FVIII levels with a slight overprediction. It highlights the importance of external validation of population PK models using real-life data.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Oncology
Mohammed Khurshed, Remco J. Molenaar, Myra E. van Linde, Ron A. Mathot, Eduard A. Struys, Tom van Wezel, Cornelis J. F. van Noorden, Heinz-Josef Kluempen, Judith V. M. G. Bovee, Johanna W. Wilmink
Summary: Mutations in the IDH1 gene are found in high-grade chondrosarcoma, high-grade glioma, and intrahepatic cholangiocarcinoma. The combination treatment of metformin and chloroquine disrupted the vulnerable metabolism of IDH1-mutated solid tumors, but did not result in a clinical response. Serum D/L-2HG ratio and ddPCR could serve as biomarkers for detecting IDH1 mutations in these patients.
Article
Hematology
Sebastiaan D. T. Sassen, Ron A. A. Mathot, Rob Pieters, Valerie de Haas, Gertjan J. L. Kaspers, Cor van den Bos, Wim J. E. Tissing, D. Maroeska W. W. te Loo, Marc B. Bierings, Inge M. van Der Sluis, C. Michel Zwaan
Summary: This study aimed to evaluate the pharmacokinetics of prednisolone in the treatment of paediatric ALL and found that unbound prednisolone plasma concentrations correlated with age, but not with disease parameters or treatment outcomes. Poor responders, high-risk and relapsed patients showed lower exposure compared to good responders, suggesting a need for further research in this area.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Pharmacology & Pharmacy
Stan J. F. Hartman, Parth J. Upadhyay, Nienke N. Hagedoorn, Ron A. A. Mathot, Henriette A. Moll, Michiel van der Flier, Michiel F. Schreuder, Roger J. Bruggemann, Catherijne A. Knibbe, Saskia N. de Wildt
Summary: Ceftriaxone pharmacokinetics in critically ill children were determined using population pharmacokinetic modeling. Dosing guidelines were proposed for adequate target attainment.
CLINICAL PHARMACOKINETICS
(2021)
Article
Hematology
Jing Zhu, Yi Shuan Wu, Ryan J. Beechinor, Ryan Kemper, Laura H. Bukkems, Ron A. A. Mathot, Marjon H. Cnossen, Daniel Gonzalez, Sheh-Li Chen, Nigel S. Key, Daniel J. Crona
Summary: This study aimed to validate a popPK model for perioperative FVIII use in hemophilia A patients and develop a modified model for UNC patients. The results showed that continuous infusion method improved target attainment and reduced total FVIII usage compared to intermittent bolus administration.
Article
Dermatology
Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek
Summary: This study investigated the changes in serum drug concentrations, anti-drug antibody (ADA) levels, and predictors for successful dose reduction of adalimumab, ustekinumab, and etanercept for psoriasis. The results suggest that interval prolongation for dose reduction may not increase immunogenicity in psoriasis patients with low disease activity.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Hematology
Marjon H. Cnossen, Iris van Moort, Simone H. Reitsma, Moniek P. M. de Maat, Roger E. G. Schutgens, Rolf T. Urbanus, Hester F. Lingsma, Ron A. A. Mathot, Samantha C. Gouw, Karina Meijer, Annelien L. Bredenoord, Rieke van der Graaf, Karin Fijnvandraat, Alexander B. Meijer, Emile van den Akker, Ruben Bierings, Jeroen C. J. Eikenboom, Maartje van den Biggelaar, Masja de Haas, Jan Voorberg, Frank W. G. Leebeek
Summary: The SYMPHONY consortium aims to personalize treatment for patients with an inborn bleeding disorder by understanding the mechanisms behind interindividual variations in bleeding phenotype. The consortium will investigate both diagnosed and undiagnosed patients and will focus on diagnosis, treatment, and fundamental research. Collaboration between patients and researchers from different areas of expertise is expected to enhance the impact of the consortium.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Pharmacology & Pharmacy
Renske C. F. Hebing, Imke H. Bartelink, Helen R. Gosselt, Sandra G. Heil, Mauritis C. F. J. de Rotte, Pascal H. P. de Jong, Mike T. Nurmohamed, Robert de Jonge, Ron A. A. Mathot
Summary: This study investigated the association between red blood cell methotrexate polyglutamates (MTX-PG) concentrations and response in rheumatoid arthritis patients starting methotrexate (MTX) therapy. The results showed that there was an association between RBC-MTX-PG concentrations and Disease Activity Score in 28 joints (DAS28). Based on the findings, it is suggested to increase the dose if MTX-PG concentration is below 9.15 nmol/L at month 1, continue with the same dose if the concentration is above 47 nmol/L, and consider other treatment options if the concentration is above 78 nmol/L from 3 months onwards.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
